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Abstract: 
Background: Dose-escalation of epertinib (S-222611), a new potent oral EGFR/HER2 
inhibitor, has established a recommended daily dose of 800 mg in patients with solid tumours. 
In this study, we have recruited a larger number of patients to assess further the safety, 
tolerability, pharmacokinetics (PK) and antitumour activity.  
Patients and methods: Patients with solid tumours expressing EGFR or HER2 received a 
single dose of epertinib at 800 mg on Day 1 to assess PK over 7 days, followed by continuous 
once-daily dosing from Day 8.  
Results: We treated 76 patients with breast (n = 27), upper gastrointestinal (GI; n = 30), head 
and neck (n = 12) or renal cancers (n = 7). Epertinib was well-tolerated with mostly Grade 1 
and 2 adverse events (AE).  The most frequent AE was diarrhoea, which was generally 
manageable with loperamide.  The objective response rate (ORR) in patients with heavily 
pretreated breast and upper GI cancers was 16.0% (4 PRs) and 8.3% (1CR, 1PR), respectively. 
All 6 responding patients had HER2-positive tumours; the ORR for HER2-positive breast and 
upper GI cancer populations was 19.0% and 20.0%. Partial response in the brain disease of one 
breast cancer patient lasted 7.5 months.  
Conclusion: Once-daily dosing of epertinib at 800 mg was well-tolerated, and demonstrated 
promising antitumour activity in patients with heavily pretreated HER2-positive breast and 
upper GI cancer, including those with brain metastases.  
EudraCT Number: 2009-017817-31 
Keywords: Epertinib, S-222611, EGFR, HER2, tyrosine kinase inhibitor 
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1. Introduction 
 Human epidermal growth factor receptor 2 (HER2) is known to be overexpressed in 
approximately 25% of breast cancers and around 20% of gastric cancers, and is associated with 
poor clinical outcome [1, 2].  Trastuzumab, a monoclonal antibody that binds to the 
extracellular domain of HER2, has been established for HER2-positive breast cancer treatment 
in the metastatic and early settings, and for HER2-positive metastatic gastric cancer treatment 
[3-5].  However, in metastatic breast cancer response rates to trastuzumab are only 15% as 
monotherapy and 49% in combination with paclitaxel [6, 7].  Also, eventually resistance 
develops in responding patients, and a significant incidence of cardiac toxicity particularly in 
patients previously exposed to anthracyclines has been reported [8].  Several aditional anti-
HER2 agents, including lapatinib, neratinib, pertuzumab and ado-trastuzumab emtansine (T-
DM1), are approved, but efficacy is still not completely satisfactory despite overall survival 
improvement with T-DM1 and pertuzumab [3, 9-13].  Therefore, there remains an unmet need 
for HER2 inhibitors that are effective and well tolerated with chronic administration.   
Epertinib (S-222611, Shionogi & Co. Ltd, Osaka, Japan) is an orally active, reversible, 
selective and potent inhibitor of epidermal growth factor receptor (EGFR), HER2 and HER4 
kinases. Compared with lapatinib, which has a similar mechanism of action, in mouse 
xenograft models epertinib showed more prolonged inhibition of EGFR and HER2 
phosphorylation in vitro, and 4-6 fold greater antitumour activity [14].  Superior survival was 
also observed in a brain metastasis model of breast cancer, with good penetration of the blood 
brain barrier [14].  
We previously performed a phase I dose-escalation study in 33 patients with solid 
tumours expressing EGFR and/or HER2 [15]. Oral epertinib was well tolerated at doses 
ranging from 100 mg to 1600 mg, and a maximum tolerated dose was not reached. Drug 
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exposure increased dose-proportionally over a range from 100 mg to 800 mg and tumour 
responses were observed across a range of doses. Based on these results, a dose of 800 mg was 
selected for further study. We now report an extended study of epertinib in patients with 
advanced solid tumours over-expressing EGFR and/or HER2. 
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2. Methods 
2.1. Patients 
Eligible patients were ≥ 18 years old with histologically and/or cytologically confirmed EGFR 
and/or HER2-positive adenocarcinoma of the breast, with or without cerebral metastases; 
adenocarcinoma of the stomach, gastro-esophageal junction or esophagus; renal cell 
carcinoma; or squamous cell carcinoma of the head and neck, that had progressed following 
treatment with approved therapies, or for which no standard therapy was available. The EGFR 
and HER2 expression were assessed at central or local laboratories using fresh tumour biopsy 
obtained at screening or archival tissue for confirmation of the eligibility, while the 
EGFR/HER2 status assessed by the central review was used for evaluation of efficacy. Eligible 
patients were required to have Eastern Cooperative Oncology Group (ECOG) performance 
status 0 or 1, and adequate hematological, renal, hepatic and left ventricular function (≥ 50%). 
Patients with brain metastasis from HER2-positive breast cancer were allowed to be enrolled 
in this study based on the evidence showing that superior efficacy in suppressing tumour 
growth of brain metastases compared to lapatinib in an intracranial implantation mouse model 
[14]. The study was approved after review by the relevant regulatory and independent ethics 
committees (EudraCT Number: 2009-017817-31), and was conducted in accordance with the 
Declaration of Helsinki and International Conference on Harmonization Good Clinical 
Practice. All patients provided written informed consent before enrollment.  
 
2.2. Study design 
Epertinib was initially administered as a single dose on Day 1, followed by continuous daily 
dosing from Day 8 to Day 28. Patients received continuous dosing with epertinib in 28-day 
cycles until disease progression, intolerable toxicity or withdrawal of consent. The primary 
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objective was to assess further the safety and tolerability of epertinib. Secondary objectives 
included pharmacokinetics (PK) and an extended assessment of efficacy. 
 
2.3. Safety assessment 
Adverse events (AEs) were monitored and clinical laboratory parameters, weight, vital signs, 
12 lead ECGs, physical and ophthalmic examinations, cardiac function including left 
ventricular ejection fraction, and ECOG performance status were assessed at baseline and 
throughout the study, and lead II continuous monitoring was carried out for 8 hours post-dosing 
on Day 1. All AEs were coded using National Cancer Institute (NCI) Common Terminology 
Criteria for Adverse Events (CTCAE) Version 4.0. 
 
2.4. Pharmacokinetic analysis 
Blood samples for the measurement of plasma concentrations of epertinib and its active de-
alkylated and lactam metabolites were taken at the following times during treatment: Day 1 
(pre-dose, 2, 4, 6, and 12 hours post-dose), Day 2 (24 hours post-dose), Day 3 (48 hours 
post-dose), Day 5 (96 hours post-dose), Days 8, 15, 22 and 29 (pre-dose). Samples were also 
taken before dosing on Days 15 and 29 of the first two cycles of Part B.  Plasma concentration 
measurement and calculation of the PK parameters of epertinib and its active metabolites were 
performed in the same manner as described in our previous report [15]. 
 
2.5. Tumour evaluation  
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Tumour response was assessed every 8 weeks according to Response Evaluation Criteria in 
Solid Tumours (RECIST) Version 1.1 [16].  Patients who had at least one additional scan after 
baseline, and patients who had no additional scan but discontinued due to clinical disease 
progression, were considered evaluable for response.  
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3. Results 
3.1. Safety and tolerability 
 Between July 2010 and January 2014, a total of 76 patients with breast (n = 27), upper GI 
(n = 30), head and neck (n = 12) and renal cell carcinoma (n = 7) were enrolled at 9 sites in the 
United Kingdom and France. Patient demographics and baseline characteristics are 
summarised in Table 1. As shown in patient disposition (Figure S1), 14 patients (7 patients in 
Part A and 7 patients in Part B) discontinued due to treatment-emergent adverse events 
(TEAEs). Only 2 patients discontinued due to TEAEs (nausea and vomiting, and bilirubin 
elevation) that were considered drug-related. Disease progression accounted for all other 
discontinuations except for one patient who was withdrawn due to deteriorating quality of life.  
Table 2 summarises all TEAEs of any grade occurring in at least 10% of patients, and all 
Grade 3 or higher TEAEs. There were no treatment-related deaths. Epertinib at 800 mg once 
daily was well tolerated by most patients, with 21.1% (16/76) of patients requiring dose 
reduction. The majority of AEs were Grade 1 or 2 in intensity, and no significant hematological 
or biochemical toxicity was observed. Overall, the most frequently reported AEs were 
diarrhoea, nausea, rash and anorexia. Diarrhoea was generally self-limiting or effectively 
controlled with loperamide; in 10 (13.2%) patients it was Grade 3. Nausea was almost always 
Grade 1 or 2 and was effectively managed with antiemetics and dose interruptions.  Rash was 
reported in 32 (42.1%) patients, of which none was more severe than Grade 2.  There were no 
effects on ECG, and no evidence that epertinib treatment affected cardiac function. 
Bilirubin elevation was observed in 23 patients (30.3%); this elevation was Grade 3 in 5 
patients (6.6%), and Grade ≤2 in all others. The increase in bilirubin was not associated with 
any symptoms, elevation of liver enzymes or hematologic abnormalities. When the 
unconjugated and conjugated bilirubin was measured in 14 of the 23 patients, the elevation was 
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predominantly attributable to unconjugated bilirubin. Dose reduction was required due to 
bilirubin elevation in 1 patient (1.3%), and resulted in study discontinuation in one (1.3%) other 
patient. 
 
3.2. Pharmacokinetic analysis. 
The PK parameters after single administration and trough plasma concentrations after repeated 
doses at 800 mg are summarised in Table S1. Epertinib was absorbed with a median Tmax of 
4.1 hours and geometric mean Cmax of 454 ng/mL following a single oral dose. The geometric 
mean t1/2,z was 33.8 hours and steady-state was achieved within 7 days of once-daily dosing. 
The pharmacologically active dealkylated and lactam metabolites of epertinib were rapidly 
formed, and the exposures (AUC0-inf and Cmax) to these metabolites were 5-7% and 6-8% on a 
molecular basis of the parent epertinib, respectively.  
 
3.3. Clinical response. 
Sixty five of 76 patients were evaluable for tumour response. The tumour responses for each 
cancer are shown in Table S2. Two patients with gastro-esophageal junction tumours had CR 
and PR, and 4 patients with breast cancer experienced PR. The objective response rate (ORR) 
for breast, upper GI, head and neck and renal cell cancers were 16.0% (4/25), 8.3% (2/24), 0% 
(0/9) and 0% (0/7), respectively.  As shown in Table 3, all of the 4 responding breast cancer 
patients were HER2-positive, but 2 of them were EGFR-negative. All 4 responding patients 
had previously received trastuzumab, and 3 of the 4 patients were previously treated with 
lapatinib. The 2 responding upper GI cancer patients were also HER2-positive, and one was 
EGFR-negative. These two patients had been treated with trastuzumab-based therapy and 
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multiple lines of chemotherapy. The ORRs in patients with HER2-positive breast and upper GI 
cancers were 19% (4/21) and 20% (2/10), respectively.  Figures 1A and 1B demonstrate the 
changes in the sum of longest diameter of target lesions and treatment period in patients with 
breast cancer having at least one evaluable scan (n = 21), and Figures 1C and 1D in patients 
with upper GI cancers (n = 20). Two of the 4 responding patients with breast cancer continued 
on study beyond 40 weeks and the other 2 patients continued beyond 16 weeks. The patient 
with gastro-esophageal junction disease experiencing CR completed a total treatment period of 
52 weeks and another with PR continued treatment until 39 weeks. 
Five patients with brain metastases from breast cancer were evaluable for radiological 
assessment, and 4 of the 5 patients had brain and/or extra-cranial lesions for assessment by 
RECIST v1.1 (Figure 1B). One of the 4 patients whose only target lesion was a brain metastasis 
achieved PR (Figure 1E) with a sustained response of 7.5 months, and 2 patients experienced 
prolonged SD (> 6 months).  
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4. Discussion 
This was an extended phase I study aiming to assess the safety, tolerability and PK of epertinib, 
as well as to provide a preliminary indication of antitumour activity. As suggested by the earlier 
dose-escalation study of this drug [15], once-daily oral dosing of epertinib at 800 mg was well-
tolerated with predominantly low-grade toxicities including diarrhoea, nausea, rash and 
anorexia; no Grade 3 rash, but Grade 3 diarrhoea observed in 10 patients (13.2%) and Grade 2 
in 14 out of 76 patients (18.4%). Diarrhoea probably caused by EGFR inhibition [17, 18] could 
be managed by anti-diarrhoeal medication; prophylactic use was not allowed in this study.  No 
patient required discontinuation of epertinib treatment due to diarrhoea.  There was no evidence 
of a drug-related decline in ejection fraction or effects on ECG QT interval, despite the known 
expression of HER2 on cardiac myocytes [19]. As reported in the dose-escalation study [15], 
elevation of blood bilirubin of any grade was observed in 30% of patients in the expansion 
phase but this was not associated with evidence of other hepatic or hematologic abnormalities.  
Epertinib is known to inhibit the conjugating enzyme UGT1A1 in vitro with an IC50 value of 
3.7 µmol/L, but not the multidrug resistance protein 2 (MRP2) involved in conjugated bilirubin 
transport. The elevated bilirubin was predominantly associated with unconjugated bilirubin in 
patients measured. Therefore, it is considered that the frequent elevation of total blood bilirubin 
in epertinib-treated patients arises from inhibition of UGT1A1-mediated bilirubin conjugation.   
PK parameters of epertinib at 800 mg once-daily were consistent with those reported 
previously [15]. The trough concentrations of epertinib at steady-state markedly exceeded 
those that were seen to inhibit EGFR and HER2 in vitro [14], and the t1/2 was consistent with 
the currently recommended daily dosing schedule. The active dealkylated and lactam 
metabolites which were identified in human but not in mouse have similar activity to that of 
the parent compound against HER2 and EGFR kinase; the IC50 values of the dealkylated and 
lactam metabolites are known to be 1.24 nmol/L and 2.32 nmol/L for EGFR and 6.31 nmol/L 
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and 18.89 nmol/L for HER2, respectively, which are almost equivalent to or lower than those 
for epertinib.  However, the plasma concentration of these metabolites accounted for only 5-
7% and 6-8% of the parent epertinib on a molecular basis, respectively, suggesting that the 
contribution of these metabolites to efficacy is modest.  
In this study, PRs were reported in five patients with breast or upper GI cancers who had 
been previously treated with HER2-targeting drugs, and one CR in another gastro-esophageal 
junction cancer patient previously treated with trastuzumab combination.  The response rate in 
patients with HER2-positive breast cancer was 19.0%, which compares favorably with 6.9% 
for lapatinib monotherapy and 10.3% for lapatinib plus trastuzumab for HER2-positive breast 
cancer [20]. Interestingly, we observed one PR and 2 long SDs among 5 patients with 
intracranial disease, which is of particular relevance for this challenging clinical scenario. Of 
the 24 upper GI cancer patients evaluable for response, 10 patients were HER2-positive and 
the other 14 patients were HER2-negative. Two of the 10 patients (20.0%) with HER2-positive 
upper GI cancer responded. For HER2-positive upper GI cancer, trastuzumab is combined with 
chemotherapy as a standard second-line therapy, with response rates reported to be 37.0% 
(17/46) in trastuzumab-naïve patients [21] and 9.3% (3/32) in trastuzumab-refractory patients 
[22]. These preliminary data on the activity of epertinib in HER2-positive upper GI cancer are 
promising and warrant further evaluation.  
All the patients with head and neck and renal cancers included in this trial were EGFR-
positive but HER2-negative, and no response was observed in these cancers. Overall, none of 
the 31 patients with HER2-negative cancers enrolled in the expansion phase study responded. 
In the earlier dose-escalation, 18.2% (4/22) of patients whose tumours were HER2-negative 
and EGFR-positive responded, including 3 PRs in upper GI cancer and 1 PR in renal cancer, 
but the response was lower than the 30.0% (3/10) observed in patients with HER2-positive 
cancers. Combining the data from the dose-escalation and expansion phases suggests that 
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HER2-positive status is a better predictive marker for the activity of epertinib than EGFR over-
expression, although EGFR inhibition may also contribute in part to the efficacy of epertinib. 
Additional pan-erbB inhibitors have been studied in breast cancer patients selected for HER2-
positivity [23, 24]. 
 In conclusion, continuous once-daily dosing with oral epertinib is well tolerated, and 
shows encouraging signs of antitumour activity particularly in patients with HER2-positive 
breast cancer with or without brain metastasis, even after previous treatment with HER2-
targeted therapies, and also in patients with HER2-positive upper GI cancer. Based on these 
findings, a phase 1/2 study of epertinib in combination with trastuzumab, or with trastuzumab 
plus chemotherapy, was initiated in patients with HER2-positive breast cancer, including those 
with brain metastases.    
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Figure legend 
Figure 1 
Antitumour activity. Response in target lesions (A and C), and duration of response and 
treatment exposure (B and D), in the patients with breast (A and B, n = 21) and upper GI 
cancers (C and D, n = 20), according to HER2 and EGFR status. Partial response in a 43-year-
old patient with brain metastases from HER2-positive breast cancer who received epertinib 
monotherapy at 800 mg (E). This patient, who had previously been treated with HER2-based 
therapies including trastuzumab, lapatinib and capecitabine, had a target lesion in the brain for 
evaluation of tumour response according to RECIST version 1.1. The response was observed 
at 16 weeks and continued until 40 weeks.  
BM: Patients with brain metastases. a Not evaluated by central review but HER2-positive by 
local assessment.   
 
